These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 9324718)

  • 1. [Significance of left ventricular hypertrophy in primary hypertension and therapeutic modification by antihypertensive drugs].
    Schiemann AL; Stimpel M
    Praxis (Bern 1994); 1997 Jul; 86(27-28):1101-6. PubMed ID: 9324718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antihypertensive treatment and left ventricular hypertrophy].
    Agabiti-Rosei E; Muiesan ML; Rizzoni D
    Ann Ital Med Int; 1993 Oct; 8 Suppl():97S-103S. PubMed ID: 8117529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Regression of left ventricular hypertrophy in hypertensive patients].
    Bosa Ojeda F; García González M; Domínguez Rodríguez A; Barragán Acea A; Miralles Ibarra JM; Lacalzada Almeida J; de Armas Trujillo D
    Rev Esp Cardiol; 1997; 50 Suppl 4():74-6. PubMed ID: 9411592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
    Gradman AH; Alfayoumi F
    Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Left ventricular hypertrophy and cardiovascular risk in hypertension].
    Amabile G
    Ann Cardiol Angeiol (Paris); 1998 Feb; 47(2):86-90. PubMed ID: 9772934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertensive heart disease.
    Diamond JA; Phillips RA
    Hypertens Res; 2005 Mar; 28(3):191-202. PubMed ID: 16097361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive drugs and the heart.
    Diamond JA; Phillips RA
    Minerva Med; 2005 Aug; 96(4):247-60. PubMed ID: 16179892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular problems and the elderly. Hypertension and cardiac failure.
    Kelleher P
    Aust Fam Physician; 1992 Dec; 21(12):1733-6, 1739-40. PubMed ID: 1476502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Left ventricular myocardial hypertrophy in arterial hypertension: clinical significance, diagnosis, effects of antihypertensive drugs].
    Martynov AI; Ostroumova OD; Mataev VI; Gedgafpva SIu; Il'ina SV
    Klin Med (Mosk); 2000; 78(10):10-7. PubMed ID: 11220891
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlations of left ventricular hypertrophy with cardiovascular mortality.
    Sharpe N
    Int J Clin Pract Suppl; 2000 May; (110):16-22. PubMed ID: 10912303
    [No Abstract]   [Full Text] [Related]  

  • 14. Left ventricular hypertrophy in hypertensive patients in Indian primary care: prevalence and effect of treatment with sustained release indapamide.
    Lokhandwala Y; Damle A
    Curr Med Res Opin; 2004 May; 20(5):639-44. PubMed ID: 15140328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
    Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
    J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Left ventricular hypertrophy: pathogenesis, diagnosis and therapy].
    Nagy V
    Orv Hetil; 2001 Jul; 142(26):1375-83. PubMed ID: 11478033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
    Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials.
    Moser M; Hebert PR
    J Am Coll Cardiol; 1996 Apr; 27(5):1214-8. PubMed ID: 8609345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Regression of left ventricular hypertrophy with antihypertensive therapy].
    Follath F
    Ther Umsch; 1998 Sep; 55(9):539-41. PubMed ID: 9789465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.